Switzerland-headquartered Sandoz (SDZ,SDZNY) manufacturing generic and biosimilar medicines on Thursday reported higher sales for the 3 months and 9 months ended September 2025.
Net sales for the third quarter were $2.8 billion, up by 6 percent at constant currencies and by 7 percent at comparable growth rates from the level of $2.6 billion recorded in the corresponding prior-year period.
Net-sales growth was primarily driven by the performance of biosimilars, which continue to benefit from an extensive pipeline and launch program.
Net sales for the 9 months ended September were $8.1 billion, up by 5 percent at constant currencies and by 6 percent at comparable growth rates from the level of $7.6 billion recorded in the year-ago period.
The company expects no change to its earlier guidance for net sales in fiscal year 2025 which is expected to grow by a mid-single-digit percentage at constant currencies.
The guidance for core EBITDA margin in fiscal 2025 has been raised to 21-22 percent from the prior guidance of around 21 percent.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.